Asymptomatic liver injury due to erythromycin stearate

J. Alcalay; S. Halevy; E. Theodor; M. Sandbank

doi:10.1177/106002808602000723

Asymptomatic liver injury due to erythromycin stearate

J. Alcalay
, S. Halevy
, E. Theodor
, M. Sandbank

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

A 73-year-old woman with rosacea, who had started treatment with erythromycin stearate 2 g/d, developed asymptomatic liver injury. The drug was discontinued and the laboratory findings of liver damage disappeared within 11 days. This is the first report of erythromycin stearate-induced asymptomatic hepatotoxicity.

Original language	English
Pages (from-to)	601-602
Number of pages	2
Journal	Drug Intelligence and Clinical Pharmacy
Volume	20
Issue number	7-8
DOIs	https://doi.org/10.1177/106002808602000723
State	Published - 1 Jan 1986
Externally published	Yes

ASJC Scopus subject areas

General Pharmacology, Toxicology and Pharmaceutics
Pharmacology (medical)

Access to Document

10.1177/106002808602000723

Cite this

@article{8f6a2ea41fd7462cb1996ff7eb1b9236,

title = "Asymptomatic liver injury due to erythromycin stearate",

abstract = "A 73-year-old woman with rosacea, who had started treatment with erythromycin stearate 2 g/d, developed asymptomatic liver injury. The drug was discontinued and the laboratory findings of liver damage disappeared within 11 days. This is the first report of erythromycin stearate-induced asymptomatic hepatotoxicity.",

author = "J. Alcalay and S. Halevy and E. Theodor and M. Sandbank",

year = "1986",

month = jan,

day = "1",

doi = "10.1177/106002808602000723",

language = "English",

volume = "20",

pages = "601--602",

journal = "Drug Intelligence and Clinical Pharmacy",

issn = "0012-6578",

publisher = "SAGE Publications Inc.",

number = "7-8",

}

TY - JOUR

T1 - Asymptomatic liver injury due to erythromycin stearate

AU - Alcalay, J.

AU - Halevy, S.

AU - Theodor, E.

AU - Sandbank, M.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - A 73-year-old woman with rosacea, who had started treatment with erythromycin stearate 2 g/d, developed asymptomatic liver injury. The drug was discontinued and the laboratory findings of liver damage disappeared within 11 days. This is the first report of erythromycin stearate-induced asymptomatic hepatotoxicity.

AB - A 73-year-old woman with rosacea, who had started treatment with erythromycin stearate 2 g/d, developed asymptomatic liver injury. The drug was discontinued and the laboratory findings of liver damage disappeared within 11 days. This is the first report of erythromycin stearate-induced asymptomatic hepatotoxicity.

UR - https://www.scopus.com/pages/publications/0022469605

U2 - 10.1177/106002808602000723

DO - 10.1177/106002808602000723

M3 - Article

C2 - 3743417

AN - SCOPUS:0022469605

SN - 0012-6578

VL - 20

SP - 601

EP - 602

JO - Drug Intelligence and Clinical Pharmacy

JF - Drug Intelligence and Clinical Pharmacy

IS - 7-8

ER -

Asymptomatic liver injury due to erythromycin stearate

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this